Evidence map›Paper›PMID 27669223›Full record

ArticleInternational journal of molecular sciences2016

Designing Efficient Double RNA trans-Splicing Molecules for Targeted RNA Repair.

Clemens Hüttner, Eva M Murauer, Stefan Hainzl, Thomas Kocher, Anna Neumayer, Julia Reichelt, Johann W Bauer, Ulrich Koller

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. RNA exon editing: Splicing the way to treat human diseases.Molecular therapy. Nucleic acids · 2024
    Review
  2. Evaluating a Targeted Cancer Therapy Approach Mediated by RNAInternational journal of molecular sciences · 2022
    Article
  3. Therapeutic applications of trans-splicing.British medical bulletin · 2020
    Article
  4. Review
  5. Article
  6. RNA Trans-Splicing Modulation via Antisense Molecule Interference.International journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Clemens HüttnerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. c.huettner@salk.at.
Eva M MurauerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. e.murauer@salk.at.
Stefan HainzlEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. s.hainzl@salk.at.
Thomas KocherEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. t.kocher@salk.at.
Anna NeumayerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. a.neumayer@salk.at.
Julia ReicheltEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. j.reichelt@salk.at.
Johann W BauerDepartment of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. jo.bauer@salk.at.
Ulrich KollerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. u.koller@salk.at.
Paracelsus Medical University · AT

Funding

Austrian Science Fund FWF P 25304
6 · The paper itself

Abstract

RNA trans-splicing is a promising tool for mRNA modification in a diversity of genetic disorders. In particular, the substitution of internal exons of a gene by combining 3' and 5' RNA trans-splicing seems to be an elegant way to modify especially large pre-mRNAs. Here we discuss a robust method for designing double RNA trans-splicing molecules (dRTM). We demonstrate how the technique can be implemented in an endogenous setting, using COL7A1, the gene encoding type VII collagen, as a target. An RTM screening system was developed with the aim of testing the replacement of two internal COL7A1 exons, harbouring a homozygous mutation, with the wild-type version. The most efficient RTMs from a pool of randomly generated variants were selected via our fluorescence-based screening system and adapted for use in an in vitro disease model system. Transduction of type VII collagen-deficient keratinocytes with the selected dRTM led to accurate replacement of two internal COL7A1 exons resulting in a restored wild-type RNA sequence. This is the first study demonstrating specific exon replacement by double RNA trans-splicing within an endogenous transcript in cultured cells, corroborating the utility of this technology for mRNA repair in a variety of genetic disorders.

Indexed as

Trans-Splicing3' Untranslated Regions5' Untranslated RegionsBase SequenceCells, CulturedCollagen Type VIIEpidermolysis BullosaExonsGenetic VectorsHEK293 CellsHumansKeratinocytesMolecular Sequence DataMutationRNA, Double-StrandedRNA, Messenger3' Untranslated Regions5' Untranslated RegionsCollagen Type VIIRNA, Double-StrandedRNA, Messengerdouble RNA trans-splicingepidermolysis bullosagenetic diseasesRNA therapytype VII collagen

Identifiers

PMID27669223
PMCPMC5085642
OpenAlexW2522882223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.